The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital spoke to the difficulty in connecting with colleagues with virtual meetings.
Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.
Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.
The anti-CD20 monoclonal antibody had an original PDUFA date of June 2020.
The professor and head of the department of neurology at the University of Minnesota spoke to the recent findings of a study of Boston Scientific's multiple independent contact current-controlled device for deep brain stimulation.
Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.
The study authors noted that the findings suggest that integrating a cost-effective and safe intervention such as yoga into the management of migraine would be beneficial.
The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital discussed the current state of research in epilepsy care.
Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.
The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.
This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in patients who have a high cardiovascular event risk, but without a history of heart attack or stroke.
The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.
The vice president of Global Program Leadership in Neurology and Immunology at EMD Serono discussed the recent long-term phase 2 data on evobrutinib presented at CMSC 2020.
From post-implantation screening to 3 months, those in the active treatment arm reported a mean improvement of 3.03 more hours of on time than the control group with Boston Scientific’s deep brain stimulation device.
Patients with acute large ischemic and hemorrhage stroke had much higher mortality risk adjusted for age.
Neurology News Network for the week ending May 30, 2020.
Sarah Morrow, MD, MS, presents her lecture titled, "A Clinician’s Guide to Cognition in MS" as part of the 2020 CMSC Virtual Annual Meeting.
Jennifer Graves, MD, PhD, presents her lecture titled, "The Role of Biological Aging in MS Progression" as part of the 2020 CMSC Virtual Annual Meeting.
Riley Bove, MD, presents her lecture titled, "Caring for Women Across the Reproductive Lifespan" as part of the 2020 CMSC Virtual Annual Meeting.
Horea Rus, MD, PhD, delivers his lecture titled, "The Role of Complement in MS" as part of the 2020 CMSC Virtual Annual Meeting.
Sergio Baranzini, PhD, presents his lecture titled, "Genetics Update" as part of the 2020 CMSC Virtual Annual Meeting.
Mark Freedman, MSc, MD, presents the John F. Kurtzke Lecture, titled "Stem Cell Research Update" as part of the 2020 CMSC Virtual Annual Meeting.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.
Following the 2020 Consortium of Multiple Sclerosis Centers Virtual Annual Meeting, the organization has scheduled a mini poster session and product theaters for June 1-14.
Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.
The consultant for the Muscular Dystrophy Association’s Chief Medical Advisory Team and associate professor of neurology at Columbia University offered his perspective on some of the latest news in ALS.
An analysis of data from the phase 3 development of cladribine (Mavenclad; EMD Serono) showed that the incidence of treatment-emergent adverse events was low and most were mild in intensity.
Laura Safar, MD, presents her lecture titled, "Use of Psychotropics in MS: Antidepressants, Anti-anxiety Agents, Mood Stabilizers, Hypnotics, Antipsychotics, and Cognitive Enhancers" as part of the 2020 CMSC Virtual Annual Meeting.
Allen Bowling, MD, PhD, presents his lecture titled, "Cannabis and MS: Efficacy, Safety, Drug Interactions, and Research Update" as part of the 2020 CMSC Virtual Annual Meeting.
Marketed as Tauvid by Avid Radiopharmaceuticals, the flortaucipir F18 IV injection is indicated to be used with PET imaging to assess the distribution and density of aggregated tau neurofibrillary tangles.
